サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1449251

レナリドミド市場、シェア、規模、動向、産業分析レポート：タイプ別、用途別、エンドユーザー別、用量別、地域別、セグメント別予測、2024年～2032年

Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.94円
レナリドミド市場、シェア、規模、動向、産業分析レポート：タイプ別、用途別、エンドユーザー別、用量別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年02月24日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、レナリドミドの世界市場規模は2032年までに156億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

レナリドミドの成長は、世界のがん患者数の増加の影響を強く受けています。多発性骨髄腫、骨髄異形成症候群、リンパ腫患者の治療におけるこの薬剤の高い効率性は、マーケットプレースでの需要を促進すると予想されます。製薬会社はレナリドミドの販売にレブラミドをブランド名として使用しています。

レナリドミド市場におけるブランドカバレッジを拡大するための製薬企業によるイニシアチブの高まりは、医薬品へのアクセシビリティを高めることができるため、世界市場の成長を刺激する可能性が高いです。例えば、ナトコ・ファーマは2023年3月、販売代理店のテバ・ファーマシューティカルズを通じて、米国でレブリミドの最新バージョンとして2.5mgと20mgの強度を追加したことを発表しました。

さらに、製薬会社はレナリドミドに関する市場開拓に取り組んでおり、世界市場の拡大を牽引しています。Start on Therapeuticsの報告書、STAR-LLDによると、低用量のレナリドミドの血液への注入は、一部の骨髄腫患者においてレブリミドを上回る最適な治療法であることが実証されました。

血液がんの罹患率の増加は、マーケットプレースにおけるレナリドミドを含む薬剤の必要性を促進し、その深い治療能力を後押ししています。米国がん協会2023年報告書によると、米国ではがんによる死亡者数は609,820人、新規患者数は1,958,310人と推定されています。この動向は、患者にとってのレナリドミドの利用しやすさを高める必要性を強調しています。

製薬会社は、レナリドミドの製造に関連する特許問題を和解で解決しつつあり、世界市場における同薬の供給増加に寄与しています。例えば、2023年、サン・ファーマはセルジーン・コーポレーションとの和解契約締結後、USFDAから複数の強度のジェネリック・レナリドミド・カプセルの販売承認を取得しました。これにより、米国では2026年1月以降、数量に制限なく製造できるようになり、予測期間中、この著名な抗がん剤の供給に弾みがつくことになります。

レナリドミド市場レポートハイライト

5mgカプセルセグメントは、その柔軟性から今後数年間で最も高い成長が見込まれます。

多発性骨髄腫の治療におけるレナリドミドの顕著な実績により、多発性骨髄腫セグメントが最大の市場シェアを占めています。

病院セグメントは、病院を受診するがん患者数の増加により、より大きな収益シェアを占めると予測されます。

APACは、がんに起因する合併症患者の増加により、最も速い成長を記録すると予測されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のレナリドミド市場に関する洞察

  • レナリドミド-業界スナップショット
  • レナリドミド市場力学
    • 促進要因と機会
      • 多発性骨髄腫の発生率の増加
      • レナリドミドの新しい摂取方法の開発に関する調査が増加
    • 抑制要因と課題
      • 医薬品開発コストの上昇
  • PESTLE分析
  • レナリドミドの業界動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のレナリドミド市場、種類別

  • 主な調査結果
  • イントロダクション
  • 5mgカプセル
  • 10mgカプセル
  • 15mgカプセル
  • 25mgカプセル

第6章 世界のレナリドミド市場、用途別

  • 主な調査結果
  • イントロダクション
  • 多発性骨髄腫（MM）
  • 骨髄異形成症候群（MDS）
  • リンパ腫
  • その他

第7章 世界のレナリドミド市場、エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院
  • がん治療センター
  • 調査機関

第8章 世界のレナリドミド市場、用量別

  • 主な調査結果
  • イントロダクション
  • カプセル
  • タブレット

第9章 世界のレナリドミド市場、地域別

  • 主な調査結果
  • イントロダクション
    • レナリドミド市場評価、地域別、2019-2032
  • レナリドミド市場-北米
    • 北米：レナリドミド市場、タイプ別、2019-2032年
    • 北米：レナリドミド市場、用量別、2019-2032年
    • 北米：レナリドミド市場、用途別、2019-2032年
    • 北米：レナリドミド市場、エンドユーザー別、2019-2032年
    • レナリドミド市場-米国
    • レナリドミド市場- カナダ
  • レナリドミド市場- 欧州
    • 欧州：レナリドミド市場、タイプ別、2019-2032
    • 欧州：レナリドミド市場、用量別、2019-2032
    • 欧州：レナリドミド市場、用途別、2019-2032年
    • 欧州：レナリドミド市場、エンドユーザー別、2019-2032
    • レナリドミド市場- 英国
    • レナリドミド市場- フランス
    • レナリドミド市場- ドイツ
    • レナリドミドマーケット-イタリア
    • レナリドミド市場- スペイン
    • レナリドミド市場- オランダ
    • レナリドミド市場- ロシア
  • レナリドミド市場- アジア太平洋
    • アジア太平洋：レナリドミド市場、タイプ別、2019-2032
    • アジア太平洋：レナリドミド市場、用量別、2019-2032
    • アジア太平洋：レナリドミド市場、用途別、2019～2032年
    • アジア太平洋：レナリドミド市場、エンドユーザー別、2019～2032年
    • レナリドミド市場- 中国
    • レナリドミド市場- インド
    • レナリドミド市場- 日本
    • レナリドミド市場- マレーシア
    • レナリドミド市場- インドネシア
    • レナリドミド市場- 韓国
  • レナリドミド市場-中東およびアフリカ
    • 中東およびアフリカ：レナリドミド市場、タイプ別、2019-2032
    • 中東およびアフリカ：レナリドミド市場、用量別、2019-2032
    • 中東およびアフリカ：レナリドミド市場、用途別、2019-2032年
    • 中東およびアフリカ：レナリドミド市場、エンドユーザー別、2019～2032年
    • レナリドミド市場- サウジアラビア
    • レナリドミド市場- 南アフリカ
    • レナリドミド市場- イスラエル
    • レナリドミド市場- アラブ首長国連邦
  • レナリドミド市場-ラテンアメリカ
    • ラテンアメリカ：レナリドミド市場、タイプ別、2019-2032年
    • ラテンアメリカ：レナリドミド市場、用量別、2019-2032
    • ラテンアメリカ：レナリドミド市場、用途別、2019-2032年
    • ラテンアメリカ：レナリドミド市場、エンドユーザー別、2019-2032年
    • レナリドミド市場- メキシコ
    • レナリドミド市場- ブラジル
    • レナリドミド市場- アルゼンチン

第10章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Ablynx（Belgium）
  • Actiza（India）
  • Celgene（US）
  • Celltrion（South Korea）
  • Dexa Medical（Indonesia）
  • Exova（UK）
  • LEO Pharma（Denmark）
  • Natco Pharma（India）
  • Toyama Chemical（Japan）
図表

List of Tables

  • Table 1 Global Lenalidomide Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Lenalidomide Market, by Application, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Lenalidomide Market, by End-User, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Lenalidomide Market, by Dosage, by Region, 2019-2032 (USD Billion)
  • Table 5 Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 8 North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 9 North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 10 U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 11 U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 12 U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 13 U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 14 Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 18 Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 19 Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 21 Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 22 Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 23 Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 25 Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 26 France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 27 France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 28 France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 30 UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 31 UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 32 UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 33 UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 34 Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 35 Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 37 Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 42 Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 43 Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 44 Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 45 Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 46 Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 47 Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 48 Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 49 Russia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 54 China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 55 China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 56 China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 57 China: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 58 Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 59 Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 60 Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 61 Japan: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 62 India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 63 India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 64 India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 India: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 74 South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 75 South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 76 South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 South Korea: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 78 Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 81 Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 82 Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 83 Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 84 Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 85 Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 86 Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 87 Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 88 Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 89 Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 90 Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 91 Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 92 Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 93 Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 98 UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 99 UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 100 UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 101 UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 106 South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 107 South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 108 South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 109 South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 110 Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 111 Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 112 Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 113 Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Lenalidomide Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Dosage
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Lenalidomide Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Dosage
  • Figure 9. Global Lenalidomide Market, by Dosage, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Lenalidomide Market, by Application, 2021 & 2030 (USD Billion)
  • Figure 12. Market by End-User
  • Figure 13. Global Lenalidomide Market, by End-User, 2021 & 2030 (USD Billion)
目次
Product Code: PM4437

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032, according to a new study by Polaris Market Research. The report "Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of lenalidomide is highly influenced by the increasing number of cancer cases worldwide. The higher efficiency of this drug in treating multiple myeloma, myelodysplastic syndromes, and lymphoma patients is anticipated to promote its demand in the marketplace. Pharmaceutical companies use Revlimid as a brand name in the marketing of lenalidomide.

The rising initiatives by pharmaceutical companies to expand their brand coverage in the lenalidomide market are likely to stimulate the growth of the global market, as they can enhance the accessibility of medicine. For instance, in March 2023, Natco Pharma unveiled the additional strengths of Revlimid in its latest version with 2.5 mg and 20 mg strengths in the United States through its marketing agent, Teva Pharmaceuticals.

Furthermore, pharmaceutical firms are engaging in development activities related to lenalidomide, driving the expansion of the global market. According to the Start on Therapeutics report, STAR-LLD, the infusion of lower-dose lenalidomide into the blood was demonstrated to be the optimal treatment over Revlimid in some myeloma patients.

The increasing incidence of blood cancer is facilitating the need for drugs, including lenalidomide, in the marketplace, driven by its profound ability to treat the disease. According to the American Cancer Society 2023 Report, in the United States, there will be 609,820 deaths caused by cancer, and the estimated number of new cases is 1,958,310. This trend is emphasizing the need to enhance the accessibility of lenalidomide for patients.

Pharmaceutical firms are resolving patent issues associated with the production of lenalidomide with the settlements, contributing to the increased supply of this drug in the global market. For instance, in 2023, Sun Pharma received approval from the USFDA to market generic lenalidomide capsules in several strengths after entering into a settlement agreement with Celgene Corporation. With this, it can produce an unlimited quantity after January 2026 in the U.S., fueling the supply of this prominent cancer drug during the forecast period.

Lenalidomide Market Report Highlights

5mg capsules segment is anticipated to witness the highest growth in the coming years due to its flexibility.

Multiple myeloma segment accounted for the largest market share owing to the prominent performance of lenalidomide in treating multiple myeloma.

Hospitals segment is projected to experience a larger revenue share due to the rising number of cancer patients consulting hospitals.

APAC is projected to register the fastest growth attributable to the increasing number of patients with cancer-based medical complications.

The global players include Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma, Natco Pharma, & Toyama Chemical.

Polaris Market Research has segmented the lenalidomide market report based on type, application, end-user, dosage, and region:

Lenalidomide, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • 5mg Capsules
  • 10mg Capsules
  • 15mg Capsules
  • 25mg Capsules

Lenalidomide, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Lymphoma
  • Others

Lenalidomide, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

Lenalidomide, Dosage Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsules
  • Tablets

Lenalidomide, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Lenalidomide Market Insights

  • 4.1. Lenalidomide - Industry Snapshot
  • 4.2. Lenalidomide Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The rising incidence of multiple myeloma
      • 4.2.1.2. The increasing research studies on developing new ways of having lenalidomide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Higher costs of drug development
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Lenalidomide Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Lenalidomide Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • 5.3. 5mg Capsules
    • 5.3.1. Global Lenalidomide Market, by 5mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.4. 10mg Capsules
    • 5.4.1. Global Lenalidomide Market, by 10mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.5. 15mg Capsules
    • 5.5.1. Global Lenalidomide Market, by 15mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.6. 25mg Capsules
    • 5.6.1. Global Lenalidomide Market, by 25mg Capsules, by Region, 2019-2032 (USD Billion)

6. Global Lenalidomide Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Multiple myeloma (MM)
    • 6.3.1. Global Lenalidomide Market, by Multiple myeloma (MM), by Region, 2019-2032 (USD Billion)
  • 6.4. Myelodysplastic syndromes (MDS)
    • 6.4.1. Global Lenalidomide Market, by Myelodysplastic syndromes (MDS), by Region, 2019-2032 (USD Billion)
  • 6.5. Lymphoma
    • 6.5.1. Global Lenalidomide Market, by Lymphoma, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Lenalidomide Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Lenalidomide Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Lenalidomide Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 7.4. Cancer Treatment Centers
    • 7.4.1. Global Lenalidomide Market, by Cancer Treatment Centers, by Region, 2019-2032 (USD Billion)
  • 7.5. Research Institutes
    • 7.5.1. Global Lenalidomide Market, by Research Institutes, by Region, 2019-2032 (USD Billion)

8. Global Lenalidomide Market, by Dosage

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • 8.3. Capsules
    • 8.3.1. Global Lenalidomide Market, by Capsules, by Region, 2019-2032 (USD Billion)
  • 8.4. Tablets
    • 8.4.1. Global Lenalidomide Market, by Tablets, by Region, 2019-2032 (USD Billion)

9. Global Lenalidomide Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Lenalidomide Market - North America
    • 9.3.1. North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.3.2. North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.3.3. North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.3.4. North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.5. Lenalidomide Market - U.S.
      • 9.3.5.1. U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.6. Lenalidomide Market - Canada
      • 9.3.6.1. Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.4. Lenalidomide Market - Europe
    • 9.4.1. Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.5. Lenalidomide Market - UK
      • 9.4.5.1. UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.6. Lenalidomide Market - France
      • 9.4.6.1. France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.7. Lenalidomide Market - Germany
      • 9.4.7.1. Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.8. Lenalidomide Market - Italy
      • 9.4.8.1. Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.9. Lenalidomide Market - Spain
      • 9.4.9.1. Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.10. Lenalidomide Market - Netherlands
      • 9.4.10.1. Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.11. Lenalidomide Market - Russia
      • 9.4.11.1. Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.5. Lenalidomide Market - Asia Pacific
    • 9.5.1. Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.5. Lenalidomide Market - China
      • 9.5.5.1. China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.6. Lenalidomide Market - India
      • 9.5.6.1. India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.7. Lenalidomide Market - Japan
      • 9.5.7.1. Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.8. Lenalidomide Market - Malaysia
      • 9.5.8.1. Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.9. Lenalidomide Market - Indonesia
      • 9.5.9.1. Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.10. Lenalidomide Market - South Korea
      • 9.5.10.1. South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.6. Lenalidomide Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.5. Lenalidomide Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.6. Lenalidomide Market - South Africa
      • 9.6.6.1. South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.7. Lenalidomide Market - Israel
      • 9.6.7.1. Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.8. Lenalidomide Market - UAE
      • 9.6.8.1. UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.7. Lenalidomide Market - Latin America
    • 9.7.1. Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.5. Lenalidomide Market - Mexico
      • 9.7.5.1. Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.6. Lenalidomide Market - Brazil
      • 9.7.6.1. Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.7. Lenalidomide Market - Argentina
      • 9.7.7.1. Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Ablynx (Belgium)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Actiza (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Celgene (US)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Celltrion (South Korea)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Dexa Medical (Indonesia)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Exova (UK)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. LEO Pharma (Denmark)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Natco Pharma (India)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Toyama Chemical (Japan)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development